Klinikum der Universität München

Mitochondria Permeability Transition versus Necroptosis in Oxalate-Induced AKI (2019) Mulay SR, Honarpisheh MM, Foresto-Neto O, Shi C, Desai J, Zhao ZB, Marschner JA, et al. Journal article Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data (2019) Sondermann W, Utikal JS, Enk AH, Schadendorf D, Klode J, Hauschild A, Weichenthal M, et al. Journal article Neurotrophic tropomyosin receptor kinase (NTRK) and nerve growth factor (NGF) are not expressed in Caucasian patients with biliary tract cancers: pooled data from three independent cohorts (2019) Westphalen CB, Preinfalk A, Kruger S, Haas M, Renz BW, Riener MO, Weber A, et al. Journal article Hypersalivation: update of the German S2k guideline (AWMF) in short form (2019) Steffen A, Jost W, Bäumer T, Beutner D, Degenkolb-Weyers S, Groß M, Grosheva M, et al. Journal article, Review article Tolerability of BRAF/MEK inhibitor combinations: Adverse event evaluation and management (2019) Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, Leipe J, Pauschinger M, et al. Journal article, Review article The myelin protein PMP2 is regulated by SOX10 and drives melanoma cell invasion (2019) Graf SA, Heppt MV, Wessely A, Krebs S, Kammerbauer C, Hornig E, Strieder A, et al. Journal article Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study (2019) Polterauer S, Schwameis R, Grimm C, Hillemanns P, Jückstock J, Hilpert F, de Gregorio N, et al. Journal article Self-attention equipped graph convolutions for disease prediction (2019) Kazi A, Krishna SA, Shekarforoush S, Kortuem K, Albarqouni S, Navab N Conference contribution Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma (2019) Van Herpen CM, Agarwala SS, Hauschild A, Berking C, Thaddeus Beck J, Schadendorf D, Jansen R, et al. Journal article Nicht-zöliakie-gluten-/weizen-sensitivität (ncgs) – ein bislang nicht definiertes krankheitsbild mit fehlenden diagnosekriterien und unbekannter häufigkeit (2019) Reese I, Schaefer C, Kleine-Tebbe J, Ahrens B, Bachmann O, Ballmer-Weber B, Beyer K, et al. Journal article